David Hardwicke is Co-Founder & Director, Head of Business Development at Aerska, a biotech developing next-generation RNA therapeutics to treat, delay and prevent diseases of the brain. Before Aerska, he worked with Pathway Bioventures, supporting investments in RNA therapeutics and gene editing companies. Earlier, he helped scale ONK Therapeutics from seed through Series A, and at AveXis (now Novartis Gene Therapies) contributed to the global launch of Zolgensma, a gene therapy for spinal muscular atrophy. He began his career co-founding Structured Immunity, a biotech spin-out applying structural and computational biology to drug discovery.